Elham Mohammadzadeh

Elham Mohammadzadeh

Auto-generated profile, based on publicly available information

Elham Mohammadzadeh

Hematology and Medical Oncology Department, Kerman Medical University, Kerman, Iran

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2018 in Current Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
TKTayebe Kermani
Tayebe Kermani
MZMaedeh Zebarjadi
Maedeh Zebarjadi
HMHassan Mehrad-Majd
Hassan Mehrad-Majd
SMSeyed-Reza Mirhafez
Seyed-Reza Mirhafez
MSMaryam Shemshian
Maryam Shemshian
MGMajid Ghayour-Mobarhan
Majid Ghayour-Mobarhan
Background/Aims: A growing body of evidence supports an important role of inflammatory-cytokines in development and progression of metabolic-syndrome (MetS), which explain, at least in part, its relationship with an increased cardiovascular-risk. Several studies have reported the therapeutic-impact of crocus-sativus in preclinical/clinical setting. Here we have explored the effects of crocus-sativus, saffron, on the modulation of twelve serum cytokines in subjects with MetS in a randomized control trial. Methods: Forty four adult volunteers, who met the diagnostic-criteria of MetS, were enrolled and randomly divided into 2 groups, to receive 100 mg/day crocus-sativus for 12 weeks. 12 cytokines, including IL-1α, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, TNF-α, MCP-1, IFN-γ, EGF, and VEGF were measured using a sandwich chemi-luminescence assays before/after therapy. Results: Our findings showed that MetS-patients who received therapy had a significantly (P<0.05) lower levels of total-cholesterol, low density-lipoprotein-cholesterol and triglyceride (TG), fasting-blood-sugar and hsCRP, however the serum concentration of high density-lipoprotein-cholesterol markedly enhanced after therapy (e.g., TG level reduced from 148.86±71.49 to 101.90±38.19 after therapy, P= 0.003). Moreover, we observed that Crocus-sativus was able to modulate the serum-concentrations of some pro-/anti-inflamatory cytokines. In particular the level of VEGF was increased from 12.64 pg/mL (95%CI: 9.60-17.67) to 16.59 (95%CI: 11.33-35.98, P= 0.033. Similar results were detected for IL-6 and EGF. Conclusion: Our findings provide a novel insight on the therapeutic role and mechanisms of this therapy in treatment of MetS patients via perturbation of cytokines and reducing the levels of triglyceride and LDL/TC, supporting further studies in a larger population.

6 January 2014 in Journal of Diabetes & Metabolic Disorders
Verified
Journal Article
Open access
MGMohammad Hossein Gozashti
Mohammad Hossein Gozashti
EMElham Mohammadzadeh
Elham Mohammadzadeh
KDKouros Divsalar
Kouros Divsalar
MSMostafa Shokoohi
Mostafa Shokoohi
Background: A number of abnormalities has been identified among drug addicted users especially heroin addicts. However, there are a few studies to assess the opium effects on thyroid hormones. the aim of the present study is to investigate the effect of opium on the thyroid function tests.Method: In this case–control, 50 male addicts, aged 20–50 years, with history of addiction to opium lasting more than two years, and 50 male non-addicts as control group were randomly selected. 10 cc blood sample was taken for measurements of TSH, total T4 and T3, free T4 and T3, and T3 resin uptake (T3RU) and 50 cc urine sample for opium testing.Results: The univariate analysis revealed that there was not a significant association between opium and serum levels of T4 and TSH, but compared with control group, a slight increase in total T3 and a decrease in T3RU were observed among addicts (P < 0.05). In multivariate analysis, opium was also found to exert a lowering effect on serum free T4 level after adjusting of age and cigarette smoking (P < 0.05).Conclusion: The findings of the present study demonstrated that opium can influence on thyroid function by increasing total T3 and decreasing T3RU and free T4 levels.

1 March 2014 in The Neuroscience Journal of Shefaye Khatam
Verified
Journal Article
Open access
EMElham Mohammadzadeh
Elham Mohammadzadeh
FAFatemeh Alipour
Fatemeh Alipour
BKBehzad Khallaghi
Behzad Khallaghi

4 April 2024 in Immunopathologia Persa
Verified
Journal Article
Open access
PDF file
EMElham Mohammadzadeh
Elham Mohammadzadeh
RARazieh Bagheri Shahzadeh Aliakbari
Razieh Bagheri Shahzadeh Aliakbari
ANAtieh Nouralishahi
Atieh Nouralishahi
AKAmin Khameneh
Amin Khameneh
BGBabak Gholamine
Babak Gholamine
EZElahe Zaremoghadam
Elahe Zaremoghadam
Introduction: Colorectal cancer (CRC) ranks as the third most prevalent diagnosed tumor worldwide. While the association between constipation and certain tumors has been established, our study aims to examine the relationship between constipation and colorectal tumors. Materials and Methods: This study employed a systematic review and meta-analysis following the PRISMA reporting guidelines. Searches were conducted without time restrictions until November 4, 2023, across various databases, including PubMed, Scopus, Web of Science, Cochrane, and the Google Scholar search engine. Data analysis was performed using STATA 14, and statistical significance was indicated by P<0.05. Results: This meta-analysis included 18 studies (9 cohort studies and 9 case-control studies) with a total sample size of 1,462,496 individuals. Overall, no significant association was found between constipation and colorectal tumors (OR: 1.09, 95% CI: 0.91–1.31), colon tumor (OR: 1.09, 95% CI: 0.89–1.34), and rectal tumor (OR: 0.95, 95% CI: 0.69–1.32). Subgroup analysis, however, revealed no statistically significant association between constipation and colorectal tumors (OR: 0.93, 95% CI: 0.76–1.14), colon tumors (OR: 0.92, 95% CI: 0.75–1.13), and rectal tumor (OR: 0.92, 95% CI: 0.65–1.21) in cohort studies. In case-control studies, constipation was associated with an increased risk of colorectal tumors (OR: 1.78, 95% CI: 1.12–2.83) and colon tumors (OR: 2.32, 95% CI: 1.58–3.42), while the association between constipation and rectal tumor in case-control studies was (OR: 1.40 (95% CI: 0.62, 2.89). Conclusion: In case-control studies, constipation emerged as a risk factor for colorectal and colon tumors, raising concerns given the high prevalence of constipation globally. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (CRD42023481321) and Research Registry (UIN: reviewregistry1741) website.